We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+15.8%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.47B
AUM Growth
+$335M
Cap. Flow
+$416M
Cap. Flow %
7.6%
Top 10 Hldgs %
51.96%
Holding
75
New
18
Increased
7
Reduced
14
Closed
5

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$165M
2
ASND icon
Ascendis Pharma A/S
ASND
+$143M
3
ITOS
iTeos Therapeutics
ITOS
+$119M
4
VXRT
Vaxart
VXRT
+$96.3M
5
MCRB icon
Seres Therapeutics
MCRB
+$79M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$434M
2
TGTX icon
TG Therapeutics
TGTX
+$91.2M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$84.2M
4
STOK icon
Stoke Therapeutics
STOK
+$26.7M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$912M 16.68%
5,909,742
+994,787
+20% +$143M
FMTX
2
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$449M 8.22%
9,011,651
– –
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
$265M 4.84%
4,826,910
– –
PCVX icon
4
Vaxcyte
PCVX
$7.65B
$261M 4.77%
5,283,818
-205,363
-4% -$8.18M
TGTX icon
5
TG Therapeutics
TGTX
$8.19B
$236M 4.32%
8,825,849
-3,962,608
-31% -$91.2M
NKTX icon
6
Nkarta
NKTX
$152M
$168M 3.08%
+5,605,129
New +$165M
AXSM icon
7
Axsome Therapeutics
AXSM
$11.7B
$145M 2.65%
2,035,132
– –
PHAT icon
8
Phathom Pharmaceuticals
PHAT
$928M
$140M 2.57%
3,825,008
– –
MCRB icon
9
Seres Therapeutics
MCRB
$45M
$134M 2.46%
+237,500
New +$79M
NVAX icon
10
Novavax
NVAX
$1.21B
$130M 2.38%
1,198,602
-3,560,231
-75% -$434M
ETNB
11
DELISTED
89bio
ETNB
$122M 2.22%
4,736,214
+1,575,000
+50% +$50M
RYTM icon
12
Rhythm Pharmaceuticals
RYTM
$7.31B
$111M 2.04%
5,140,408
-69,680
-1% -$1.6M
MGNX icon
13
MacroGenics
MGNX
$233M
$110M 2.02%
4,375,217
-209,435
-5% -$5.72M
EIDX
14
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$109M 2%
2,163,271
+600
+0% +$27K
ITOS
15
DELISTED
iTeos Therapeutics
ITOS
$109M 1.99%
+4,417,258
New +$119M
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
$98.4M 1.8%
5,488,424
+1,811,000
+49% +$44.4M
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
$96.9M 1.77%
941,086
+160,922
+21% +$24.1M
ADAP
18
DELISTED
Adaptimmune Therapeutics
ADAP
$90.4M 1.65%
11,329,581
-1,722,883
-13% -$15.1M
TRIL
19
DELISTED
Trillium Therapeutics Inc.
TRIL
$87.6M 1.6%
6,162,694
– –
ARVN icon
20
Arvinas
ARVN
$530M
$86.7M 1.59%
3,672,872
– –
TVTX icon
21
Travere Therapeutics
TVTX
$5.17B
$85.6M 1.57%
4,635,687
– –
KALA icon
22
KALA BIO
KALA
$12.5M
$81.6M 1.49%
4,354
– –
BDTX icon
23
Black Diamond Therapeutics
BDTX
$95.1M
$78.3M 1.43%
2,589,904
– –
LEGN icon
24
Legend Biotech
LEGN
$3.65B
$74.3M 1.36%
2,408,292
-73,650
-3% -$2.48M
IGMS
25
DELISTED
IGM Biosciences
IGMS
$72.5M 1.33%
982,723
– –
1
2 3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, RA Capital Management held 75 positions worth $5.47B, up 6.5% from $5.13B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

RA Capital Management deployed $416M of net new capital in Q3 2020, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was Nkarta: 5,605,129 shares worth $168M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Novavax, an estimated $434M trimmed.

  • RA Capital Management's largest Q3 2020 buy was Nkarta: 5,605,129 shares worth $168M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q3 2020, an estimated $143M increase.
  • RA Capital Management's biggest Q3 2020 reduction was Novavax, cutting an estimated $434M.
  • RA Capital Management fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $84.2M.
  • RA Capital Management's ten largest holdings make up 52% of its $5.47B portfolio in Q3 2020.
  • RA Capital Management opened 18 new positions and closed 5 in Q3 2020.
  • RA Capital Management's portfolio value rose 6.5% quarter-over-quarter to $5.47B.

Based on RA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.